Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Sells $107,085.07 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne C. Whitfield sold 2,137 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $107,085.07. Following the transaction, the insider now owns 46,355 shares of the company’s stock, valued at $2,322,849.05. The trade was a 4.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Tarsus Pharmaceuticals Price Performance

TARS stock traded up $0.36 during mid-day trading on Thursday, hitting $49.91. 618,361 shares of the stock were exchanged, compared to its average volume of 639,768. The business has a fifty day moving average price of $48.54 and a 200 day moving average price of $45.06. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of -13.10 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. On average, sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Crowley Wealth Management Inc. bought a new stake in Tarsus Pharmaceuticals in the fourth quarter worth $25,000. GF Fund Management CO. LTD. purchased a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $44,000. R Squared Ltd purchased a new position in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $53,000. FMR LLC lifted its stake in shares of Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after acquiring an additional 3,537 shares during the last quarter. Finally, Quarry LP purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at about $166,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Wall Street Analyst Weigh In

TARS has been the subject of a number of research reports. Jefferies Financial Group increased their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Guggenheim reaffirmed a “buy” rating and issued a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. HC Wainwright reissued a “buy” rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Barclays cut their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Finally, Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.